Fwd: Mix of Good, Bad News for ImClone's Erbitux at ASCO

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 3, 2008 at 1:20 AM
Subject: Mix of Good, Bad News for ImClone's Erbitux at ASCO
To: mesothelioma77@gmail.com

While data from the much-anticipated FLEX Phase III study showed that ImClone Systems Inc.'s Erbitux prolonged life by about five weeks for patients with non-small-cell lung cancer , findings from another study ...

Tue, 03 Jun 2008 02:57:31 GMT

---

Source: http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=47740
--
 
~
Powered by RssFwd, a service of Blue Sky Factory, Inc